Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes - PubMed (original) (raw)
Randomized Controlled Trial
. 2020 Oct 8;383(15):1425-1435.
doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
Richard Pratley 1, Samuel Dagogo-Jack 1, James Mancuso 1, Susan Huyck 1, Urszula Masiukiewicz 1, Bernard Charbonnel 1, Robert Frederich 1, Silvina Gallo 1, Francesco Cosentino 1, Weichung J Shih 1, Ira Gantz 1, Steven G Terra 1, David Z I Cherney 1, Darren K McGuire 1; VERTIS CV Investigators
Collaborators, Affiliations
- PMID: 32966714
- DOI: 10.1056/NEJMoa2004967
Randomized Controlled Trial
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P Cannon et al. N Engl J Med. 2020.
Abstract
Background: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.
Methods: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.
Results: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.
Conclusions: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Copyright © 2020 Massachusetts Medical Society.
Similar articles
- Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK; VERTIS CV Investigators. Cosentino F, et al. Circulation. 2020 Dec 8;142(23):2205-2215. doi: 10.1161/CIRCULATIONAHA.120.050255. Epub 2020 Oct 7. Circulation. 2020. PMID: 33026243 Free PMC article. Clinical Trial. - Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Diabetologia. 2021 Jun;64(6):1256-1267. doi: 10.1007/s00125-021-05407-5. Epub 2021 Mar 4. Diabetologia. 2021. PMID: 33665685 Free PMC article. Clinical Trial. - Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, Lawrence D, Jones PLS, Liu J, Adamsons I, Dagogo-Jack S. Pratley RE, et al. Lancet Healthy Longev. 2023 Apr;4(4):e143-e154. doi: 10.1016/S2666-7568(23)00032-6. Lancet Healthy Longev. 2023. PMID: 37003273 Clinical Trial. - Ertugliflozin: First Global Approval.
Markham A. Markham A. Drugs. 2018 Mar;78(4):513-519. doi: 10.1007/s40265-018-0878-6. Drugs. 2018. PMID: 29476348 Review. - Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
Hu J, Deng A, Zhao Y. Hu J, et al. Expert Opin Pharmacother. 2018 Nov;19(16):1841-1847. doi: 10.1080/14656566.2018.1525360. Epub 2018 Sep 24. Expert Opin Pharmacother. 2018. PMID: 30223693 Review.
Cited by
- Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease.
Miguel V, Shaw IW, Kramann R. Miguel V, et al. Nat Rev Nephrol. 2024 Sep 17. doi: 10.1038/s41581-024-00889-z. Online ahead of print. Nat Rev Nephrol. 2024. PMID: 39289568 Review. - Assessment of the effect of the SLC5A2 gene on eGFR: a Mendelian randomization study of drug targets for the nephroprotective effect of sodium-glucose cotransporter protein 2 inhibition.
Liu G. Liu G. Front Endocrinol (Lausanne). 2024 Aug 29;15:1418575. doi: 10.3389/fendo.2024.1418575. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39268232 Free PMC article. - SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART.
Rosén HC, Mohammad MA, Jernberg T, James S, Oldgren J, Erlinge D. Rosén HC, et al. Lancet Reg Health Eur. 2024 Aug 21;45:101032. doi: 10.1016/j.lanepe.2024.101032. eCollection 2024 Oct. Lancet Reg Health Eur. 2024. PMID: 39262451 Free PMC article. - Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials.
Wang F, Li C, Cui L, Gu S, Zhao J, Wang H. Wang F, et al. Front Endocrinol (Lausanne). 2024 Aug 23;15:1436217. doi: 10.3389/fendo.2024.1436217. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39247919 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical